Jove
Visualize
Contact Us

Related Concept Videos

Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gaps Between Guidelines and Practice in Patients with Hypertension and Type 2 Diabetes: A Nationwide Cross-Sectional Study (SNAPSHOT-Brazil Study).

Journal of clinical medicine·2026
Same author

Screening for CKD in undiagnosed populations with diabetes and hypertension: lessons from the SEARCH study.

Jornal brasileiro de nefrologia·2026
Same author

Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement.

The lancet. Diabetes & endocrinology·2025
Same author

Continuous glucose monitoring system in diabetes in pregnancy: a narrative review.

Diabetology & metabolic syndrome·2025
Same author

Glucose alarms approach with flash glucose monitoring system: a narrative review of clinical benefits.

Diabetology & metabolic syndrome·2025
Same author

Advance Insulin Injection Technique and Education With FITTER Forward Expert Recommendations.

Mayo Clinic proceedings·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 21, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

[Does brittle diabetes exist as a clinical entity?].

Freddy Goldberg Eliaschewitz1, Denise Reis Franco

  • 1Núcleo de Terapia Celular e Molecular, Universidade de São Paulo, São Paulo, SP, Brasil. freddy.g@uol.com.br

Arquivos Brasileiros De Endocrinologia E Metabologia
|August 4, 2009
PubMed
Summary

Understanding glycemic instability in type 1 diabetes mellitus (T1DM) and new treatments like insulin pumps raises questions about brittle diabetes. This article defines brittle diabetes and proposes criteria to assess glucose liability in T1DM patients.

More Related Videos

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

Related Experiment Videos

Last Updated: Jun 21, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Diabetes Research

Context:

  • Type 1 Diabetes Mellitus (T1DM) presents challenges in glycemic control.
  • Advancements in T1DM treatment include insulin pump therapy and insulin analogues.
  • The clinical entity of brittle diabetes requires clear definition.

Purpose:

  • To describe the concept of brittle diabetes.
  • To review the latest advances in T1DM treatment.
  • To propose objective criteria for evaluating glucose liability.

Summary:

  • This article explores the concept of brittle diabetes within the context of T1DM.
  • It examines the impact of modern T1DM management strategies on glycemic control.
  • The study aims to establish measurable criteria for identifying and assessing brittle diabetes.

Impact:

  • Provides a clearer understanding of brittle diabetes as a clinical concept.
  • Offers objective tools for healthcare professionals to evaluate glucose liability.
  • Contributes to improved management strategies for T1DM patients experiencing glycemic instability.